SAN DIEGO, Nov. 20, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil opened its newest office in São Paulo on Nov. 13, 2018.
"We were very fortunate to have a successful grand opening event for our new office last week," said HempMeds® Brasil Vice President Caroline Heinz. "This new space allows us more room and new opportunities to network with doctors, service patients and educate people here about the wellness benefits of CBD."
The grand opening event took place in conjunction with the CannX Brazil Conference in São Paulo. HempMeds® Mexico President Raul Elizalde joined HempMeds® Brazil Vice President Caroline Heinz for the official ribbon cutting ceremony. The new facility features a doctor's office, a clinic, an office space for the HempMeds® Brasil staff, a classroom for educational seminars, and a lounge area to promote institutional events.
The event attracted media professionals, doctors and high-profile executives in the medical and cannabis industries. Also in attendance were Norberto Fischer and his wife Katiele, who first became involved in the cannabis industry when they received the first National Agency of Sanitary Surveillance (ANVISA)-authorized import permit for HempMeds® Brasil's hemp-based cannabidiol (CBD) product Real Scientific Hemp Oil™ (RSHO™) in Brazil for their daughter Anny.
"We are committed to expanding internationally and this office opening is an important step in that growth," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "We are the first company to bring CBD to families in need in Brazil and we couldn't be more excited to expand our operations there."
HempMeds® Brasil was the first company to receive an import permit for CBD in Brazil and, after a series of historic rulings, Brazilian Health Regulatory Agency ANVISA removed CBD from Brazil's prohibited substance use list, removed the substance's import tax and is now actively subsidizing the cost of CBD for those who need financial assistance.
About HempMeds® Brasil
HempMeds® Brasil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson's, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil works on additional approvals for other indications. www.hempmeds.com.br.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
SOURCE Medical Marijuana, Inc.